Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy ...
Akebia Therapeutics, Inc. ( AKBA) announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for rare complement-mediated kidney diseases, including IgA ...
The complement cascade, a proteolytic network originally characterised for host defence, exerts multifaceted roles within the central nervous system. Under physiological conditions, complement ...
Complement 3 glomerulopathy (C3G) is a rare kidney disorder—in many cases, the exact cause is unknown. Possible C3G causes include genetic mutations, autoantibodies, and certain autoimmune conditions.
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Complement Therapeutics GmbH (CTx) – a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases – announced the completion of a €72 million Series A ...
Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...
CHAPLE syndrome is an exceptionally rare genetic disorder, with fewer than 100 patients estimated to have been diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results